Lori Solomon
MONDAY, Jan. 23, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK…
Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high…
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the…
CLL exists as either a slowly or rapidly growing cancer and has been linked with certain genetic mutations, but it has yet to be fully characterized. Previous analyses have provided only…
UTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its…
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLLBMF-219, a covalent menin inhibitor, demonstrated potency across…
Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those…